Pharmaceuticals, Biotechnology and Life Sciences
Biocept and Catalyst Pharmaceuticals announced a partnership which will provide Biocept’s Target Selector platform to screen patients diagnosed with LEMS for early onset or recurrence of small cell lung cancer (SCLC).
AMO Pharma Limited and Ranedis Pharmaceuticals,two privately held U.S. pharma companies have partnered up to develop RND-001 for rare genetic diseases, including certain lysosomal storage disorders and other diseases affecting the central nervous system.
Tiziana Life Sciences, a clinical stage biotechnology company developing targeted drugs for cancer, autoimmune and inflammatory diseases, has appointed Dr. Arun Sanyal as a new member of its Scientific Advisory Board.
The expansion of product lines and enhanced product development are fueling rising revenues and overall growth in the swelling cannabis market despite recent ambiguous reports of direction of the federal impact on the legal marijuana market
Aytu BioScience, Inc., a specialty pharmaceutical company focused on products in the field of urology, today announced the publication of journal article describing the effectiveness …
The US Food and Drug Administration (FDA) has approved Novartis’s Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
According to American Academy of Ophthalmology (AAO) nearly 25.7 million Americans over age 40 have cataracts and the number is projected to increase to 45.6 million by 2050.
Mylan has agreed to the terms of a global settlement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. related to patents for Herceptin (trastuzumab), which provides Mylan with global licenses for its trastuzumab product.
iShares NASDAQ Biotechnology exchange-traded fund has gained 13% so far this year, more than double the SPDR S&P 500 ETF’s 6.3% rise, as the potential for new drugs and mergers and acquisitions has rekindled interest in the beaten-down sector.
Data that should help unlock the sales potential of a potent new cholesterol medicine will be unveiled at the American College of Cardiology meeting this week as the future of the only rival drug rests with the courts in an ongoing patent dispute.